Phentolamine ophthalmic solution 0.75%

Phentolamine ophthalmic solution 0.75% is an alpha-adrenergic antagonist eye drop developed by Opus Genetics in collaboration with Viatris, sold as RYZUMVI. The next event is Phase 3 topline results (LYNX-3) for Phentolamine Ophthalmic Solution, expected October 2026 (source).

Also known as: RYZUMVI
Company: Opus Genetics (IRD) · Developer, in collaboration with Viatris
How it works: Alpha-adrenergic antagonist
Approved: RYZUMVI: United States, to reverse pharmacologically induced pupil dilation

Development by disease

Pharmacologically induced mydriasis	Approved
Low-light visual disturbances	Filed
Presbyopia	Filed

Upcoming events

Estimated timing · a month, quarter, half-year or year-end the company gave

Expected in October 2026

October 2026
Phentolamine Ophthalmic Solution · Phase 3 topline results (LYNX-3) · Visual disturbances · post-keratorefractive surgery · mesopic, low-contrast conditions
Opus Genetics (IRD)·Source
October 2026
Phentolamine Ophthalmic Solution · FDA decision (supplemental application) · Presbyopia
Opus Genetics (IRD)·Source

Past results and milestones

Dec 17, 2025
Viatris filed the Phentolamine sNDA for presbyopia with the FDA on December 17, 2025, as planned, supported by positive VEGA-3 Phase 3 data. Source

Trials

LYNX-3

The investment thesis, what each upcoming event depends on and the competitive landscape are on the Opus Genetics page. Upcoming FDA decisions · All drugs